Renaissance Technologies
TOVX icon

Renaissance Technologies’s Theriva Biologics TOVX Stock Holding History

Renaissance Technologies’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,148
Closed -$24.5K – 3892
2024
Q2 		$24.5K Buy
4,148
+1,408
+51% +$12.3K ﹤0.01% 3365
2024
Q1 		$32K Buy
2,740
+372
+16% +$4.35K ﹤0.01% 3546
2023
Q4 		$25K Buy
2,368
+200
+9% +$2.46K ﹤0.01% 3563
2023
Q3 		$29K Buy
2,168
+620
+40% +$9.43K ﹤0.01% 3477
2023
Q2 		$39K Buy
1,548
+160
+12% +$2.82K ﹤0.01% 3657
2023
Q1 		$24K Buy
1,388
+88
+7% +$1.82K ﹤0.01% 3797
2022
Q4 		$15K Buy
1,300
+32
+3% +$581 ﹤0.01% 4009
2022
Q3 		$31K Buy
1,268
+392
+45% +$15K ﹤0.01% 3840
2022
Q2 		$47K Buy
876
+446
+104% +$25.5K ﹤0.01% 4004
2022
Q1 		$31K Buy
430
+348
+424% +$23.7K ﹤0.01% 3969
2021
Q4 		$6K Buy
+82
New +$7.73K ﹤0.01% 3859
2021
Q1 		– Sell
-4,951
Closed -$474K – 3706
2020
Q4 		$474K Buy
4,951
+1,512
+44% +$132K ﹤0.01% 2842
2020
Q3 		$408K Sell
3,439
-119
-3% -$15.9K ﹤0.01% 2891
2020
Q2 		$455K Buy
3,558
+803
+29% +$76.5K ﹤0.01% 2910
2020
Q1 		$221K Buy
2,755
+428
+18% +$48.7K ﹤0.01% 3078
2019
Q4 		$295K Buy
2,327
+321
+16% +$34.2K ﹤0.01% 3075
2019
Q3 		$228K Buy
2,006
+260
+15% +$31.4K ﹤0.01% 3110
2019
Q2 		$240K Buy
1,746
+139
+9% +$20K ﹤0.01% 3255
2019
Q1 		$273K Buy
1,607
+204
+15% +$33.8K ﹤0.01% 3123
2018
Q4 		$196K Buy
1,403
+1,222
+675% +$290K ﹤0.01% 3140
2018
Q3 		$118K Buy
+181
New +$200K ﹤0.01% 3229
2017
Q2 		– Sell
-3
Closed -$14K – 3363
2017
Q1 		$14K Buy
+3
New +$20.9K ﹤0.01% 3182

Other funds holding TOVX

HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies's TOVX Position: Q3 2024 in Review

Renaissance Technologies sold out of Theriva Biologics (TOVX) in Q3 2024, closing a stake of 4,148 shares — an estimated $24.5K sold.

Renaissance Technologies first reported a position in TOVX in Q1 2017 and held it in 22 quarters. The position peaked at $474K in Q4 2020. 18 funds tracked by Wall St. Rank hold TOVX as of Q3 2024.

  • Renaissance Technologies reported no remaining Theriva Biologics position as of Q3 2024 after selling out during the quarter.
  • Renaissance Technologies sold 4,148 Theriva Biologics shares in Q3 2024, an estimated $24.5K.
  • Renaissance Technologies first reported a position in Theriva Biologics in Q1 2017 and held it in 22 quarters.
  • Renaissance Technologies's Theriva Biologics position peaked at $474K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2024.

Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.